Creative Biolabs is committed to delivering the next therapeutic breakthrough to help our clients the development of safer immunotherapy. Based on a well-established state-of-the-art platform, we have rich experience in performing a wide range of services required for successful cell engineering. We are pleased to provide both off-the-shelf and customized solutions to engineer LNCaP cells for cancer self-destruction.

Introduction of LNCAP Cell Line

The LNCaP cell line was isolated from a lymph node metastasis of a 50-year-old Caucasian male with confirmed prostatic adenocarcinoma in 1977. This cell line retains the characteristics of prostate cancer tumor cytology and its early differentiation function and has features that are typical of conventional adenocarcinoma of the prostate. LNCaP cells express AR and PSA, and are androgen-dependent with relatively indolent biologic behavior similar to the vast majority of the PCs encountered clinically. Most notably, LNCaP cells express a mutated version of AR, which has broader steroid-binding specificity than wild-type AR. LNCaP cells are adherent epithelial cells that grow in aggregates as well as in single cells in vitro. However, LNCaP cells gradually lose their androgen-sensitive growth characteristic upon continuous passage. This cell line is the most commonly used for prostate cancer research.

• Characteristics of LNCAP Cell Line

Studies Performed with Engineered LNCaP Cells

Some studies and clinical trials had developed allogeneic cellular immunotherapy utilizing prostate cancer cells LNCaP engineered to secrete cytokines.

• Researchers have designed vaccines based on LNCaP and PC3 cells that are genetically modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF). Phase 3 trials in patients with advanced, metastatic, hormone-refractory prostate cancer are underway.
• A phase I clinical trial has assessed IL-2- and IFN-γ -secreting LNCaP cell vaccine, showing high efficacy in inducing tumor-specific immune responses in patients with hormone-refractory prostate cancer.

Engineering LNCaP Cell Line Service

Creative Biolabs offers state-of-the-art services to build gene-modified LNCap cells that are applied to cancer immunotherapy through several strategies, such as engineering LNCaP cells with cytokine overexpression, aptamer, and aptamer-siRNA chimera. These strategies can further custom tune-up or optimization, and more. Collaborating with our custom cell services team, we can rapidly deliver the cell lines you need to keep your project on track.

Creative Biolabs is pleased to provide a number of services to meet your scientific need and projects. Our full-service workflow includes strategy design, cell engineering, self-destruction assays, ex vivo assessment, etc. The following is a typical service workflow and the steps that we can help move your experiment forward.

Save yourself time and hassle and have Creative Biolabs handle all aspects of your genome engineering workflow, from start to finish. Please feel free to contact us, and one of our experts will contact you to discuss how we can help.

References

1. Simons, J.W.; Sacks, N. Granulocyte-macrophage colony-stimulating factor− transduced allogeneic cancer cellular immunotherapy: The GVAX^® vaccine for prostate cancer//Urologic Oncology: Seminars and Original Investigations. Elsevier. 2006, 24(5): 419-424.
2. Brill, T.H.; et al. Allogeneic retrovirally transduced, IL-2‐and IFN-γ‐secreting cancer cell vaccine in patients with hormone refractory prostate cancer—a phase I clinical trial. The Journal of Gene Medicine: A cross‐disciplinary journal for research on the science of gene transfer and its clinical applications. 2007, 9(7): 547-560.

For Research Use Only | Not For Clinical Use